Thermo Fisher Scientific Inc. $TMO Stock Holdings Trimmed by Castle Rock Wealth Management LLC

Key Points

• Castle Rock Wealth Management cut its Thermo Fisher stake by 69.7% in the third quarter, leaving it with 1,228 shares valued at approximately $806,000. Institutional investors collectively own 89.23% of the company.
• Analysts maintain a generally positive outlook, with Thermo Fisher receiving a consensus “Moderate Buy” rating and an average price target of $634.86. Recent ratings ranged from Citigroup’s “Underperform” to UBS’s upgraded “Buy” recommendation.
• Thermo Fisher shares rose 1% to $658.23, while the company reported quarterly EPS of $6.03 and revenue of $11.99 billion, exceeding estimates; revenue increased 10.5% year over year.

Castle Rock Wealth Management LLC cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 69.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,228 shares of the medical research company's stock after selling 2,826 shares during the period. Castle Rock Wealth Management LLC's holdings in Thermo Fisher Scientific were worth $806,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Thermo Fisher Scientific in the 2nd quarter valued at $15,501,867,000. State Street Corp boosted its position in shares of Thermo Fisher Scientific by 1.4% during the 4th quarter. State Street Corp now owns 16,613,761 shares of the medical research company's stock valued at $9,633,991,000 after acquiring an additional 229,630 shares during the last quarter. Corient Private Wealth LP purchased a new stake in shares of Thermo Fisher Scientific in the second quarter valued at about $382,547,000. Bank of New York Mellon Corp acquired a new stake in Thermo Fisher Scientific during the second quarter worth about $1,974,561,000. Finally, Bank of America Corp DE purchased a new position in Thermo Fisher Scientific during the second quarter worth about $1,952,930,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Royal Bank Of Canada increased their price target on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a "sector perform" rating in a research note on Friday, July 24th. Citigroup lowered shares of Thermo Fisher Scientific from a "buy" rating to an "underperform" rating in a research report on Wednesday, September 9th. UBS Group upgraded Thermo Fisher Scientific from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $540.00 to $730.00 in a research report on Tuesday, September 8th. Morgan Stanley raised their target price on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an "overweight" rating in a research note on Friday, July 24th. Finally, Evercore set a $570.00 price target on Thermo Fisher Scientific in a research note on Monday, July 6th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and a consensus target price of $634.86.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $629.27, for a total value of $6,292,700.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares of the company's stock, valued at $77,982,284.75. The trade was a 7.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $565.00, for a total transaction of $226,000.00. Following the completion of the transaction, the chief operating officer directly owned 24,651 shares of the company's stock, valued at approximately $13,927,815. The trade was a 1.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 73,768 shares of company stock worth $44,122,820 over the last ninety days. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Trading Up 1.0%

NYSE TMO traded up $6.25 on Friday, reaching $658.23. The stock had a trading volume of 1,580,669 shares, compared to its average volume of 2,250,091. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The stock has a fifty day moving average price of $625.73 and a two-hundred day moving average price of $540.54. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $694.33. The firm has a market capitalization of $243.38 billion, a price-to-earnings ratio of 35.41, a P/E/G ratio of 2.77 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company's quarterly revenue was up 10.5% on a year-over-year basis. During the same period last year, the business posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company's portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.